Xuanzhu Bio-B (02575) rose more than 6% during the early trading session. As of the time of writing, the stock was up 2.36%, trading at HKD 52.05, with a turnover of HKD 2.9905 million.

The catalyst for the movement is the official implementation of the national reimbursement for Piroxiclib, effective January 1, 2026.

On December 7, 2025, the National Healthcare Security Administration announced the results of the 2025 National Reimbursement Drug List (NRDL) adjustment. Xuanzhu Bio's self-developed Class 1 innovative drug, the CDK4/6 inhibitor Piroxiclib Tablets, was successfully included in the list, bringing new reimbursement benefits for patients with advanced breast cancer.

The company had previously stated that the outcome of this医保 negotiation will help further enhance the affordability and accessibility of Xuan Yue Ning for patients.

It is also expected to facilitate the drug's market promotion, boost sales volume, and exert a positive impact on the company's long-term operational development.

The company will actively cooperate to promote the implementation of the reimbursement policy, continuously advance hospital admission procedures, expand into core markets, and broaden market coverage, aiming to steadily improve patient access to the medication.